Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease
نویسندگان
چکیده
Background Blood-biomarkers of Alzheimer’s disease (AD) pathology have been investigated cross-sectionally in heterogenous AD cohorts and shown to detect underlying pathology, even at preclinical stages. However, longitudinal studies, including serial blood-biomarker measurements, are needed better understand whether these markers could help monitor progression. We aimed assess blood-biomarkers temporal trajectories cognitively unimpaired older adults different pathological stages as assessed by positron emission tomography (PET). This may provide insight into dynamic changes biomarkers beginning prior abnormality on PET. Method included a subset 126 from the Prevent-AD cohort. Blood was drawn baseline up four-year follow-up visits. measured Aβ42/Aβ40 ratio, pTau181 pTau231 using novel single molecular array (Simoa). All participants completed Aβ (18F-NAV4694) tau (18F-flortaucipir) PET scans, which were mostly performed latest blood collection timepoint. positivity defined global neocortical Aβ-PET retention (SUVR cut-off = 1.29), tau-PET entorhinal cortex flortaucipir binding 1.23). Using thresholds, 82 subjects classified A-T-, 29 A+T-, 15 A+T+. Linear mixed effects models used differences rate change plasma between groups. Result Amyloid-PET-positive individuals showed elevated levels pTau181, lower Aβ42/40 when compared with amyloid-PET-negative participants. Plasma greater increase over time A+T+ group A-T- (p 0.01; Figure 1). Overall, A+T- groups had 0.05, p 0.0189; 2), higher 0.0006; 3). Longitudinal did not differ Conclusion observed increased those both amyloid The slopes across despite overall level pathology.
منابع مشابه
Cognitive Impairments in Siblings of Alzheimers Disease Patients: Possible Preclinical Signs of the Disease
متن کامل
Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study.
INTRODUCTION Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials. METHODS In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healt...
متن کاملLongitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
IMPORTANCE Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the normal life span underlying AD pathologies begin to develop, their patterns of change over time, and their relationship with future cognitive decline remain to be determined. OBJECTIVE To characterize the within-person trajectori...
متن کاملPreclinical Alzheimer's disease and longitudinal driving decline
INTRODUCTION Links between preclinical AD and driving difficulty onset would support the use of driving performance as an outcome in primary and secondary prevention trials among older adults (OAs). We examined whether AD biomarkers predicted the onset of driving difficulties among OAs. METHODS 104 OAs (65+ years) with normal cognition took part in biomarker measurements, a road test, clinica...
متن کاملSubtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
The NIA-AA criteria for "preclinical" Alzheimer's disease (AD) propose a staging method in which AD biomarkers follow an invariable temporal sequence in accordance with the amyloid cascade hypothesis. However, recent findings do not align with the proposed temporal sequence and "subtle cognitive decline," which has not been definitively operationalized, may occur earlier than suggested in precl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Alzheimers & Dementia
سال: 2022
ISSN: ['1552-5260', '1552-5279']
DOI: https://doi.org/10.1002/alz.064811